RNS Number : 3776K

Open Orphan PLC

05 May 2022

Open Orphan plc

("Open Orphan" or the "Company")

hVIVO's first ever Phase II field study site study awarded

First site study awarded offering new site services since facilities expansion

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO , a subsidiary of Open Orphan, has been awarded a new study with an existing Big Pharma client to act as a vaccination site for a Phase II field study of the client's respiratory syncytial virus (RSV) vaccine candidate.

As part of the study, hVIVO will recruit 60 healthy volunteers to the Company's new site clinic at Plumbers Row, where they will then be inoculated with either the RSV vaccine candidate or a placebo. As opposed to a human challenge study, where volunteers would then be challenged and quarantined within hVIVO's FluCamp facilities, these participants will then be free to leave the facilities. Participants will then be monitored for RSV symptoms over the following months, with regular clinical check-ups at Plumbers Row, to assess the efficacy of the vaccine candidate and its ability to prevent illness through RSV. The study is expected to begin in Q3 2022 with the majority of revenue from the contract recognised in 2023.

This is the first vaccine field study the Company has been awarded since it announced the expansion of its facilities on 8 March 2022 . In addition to the core human challenge studies the expansion has enabled Open Orphan to provide a larger service offering including non-first in human Phase I trials such as PK (pharmacokinetics) studies, bridging studies and Phase II trials in patients and healthy volunteers.

The volunteers for the study will be recruited through the Company's specialist volunteer recruitment arm, FluCamp . FluCamp has decades of experience attracting suitable healthy subjects to meet recruitment requirements, primarily sourcing subjects for hVIVO trials to date. FluCamp's large database, tech-enabled platform and recently improved screening capabilities will mean that hVIVO is able to efficiently recruit and assess potential volunteers for its client's field studies in a timely and cost-effective manner.

Yamin 'Mo' Khan, Chief Executive Officer of Open Orphan, said : "This is a significant award for Open Orphan as it is our first study as a site. To date we have mainly acted as a Contract Research Organisation to provide either challenge studies, laboratory or consulting services. Although we have acted as a site as part of the challenge studies, we have not provided stand-alone site services. We expanded our facilities at Plumbers Row in March of this year with the aim to provide site services. It is a great testament to the team that they have been able to fulfil site activity work in such a short timeframe. There are a great number of synergies between our core challenge study activities and new the site services, this will help us to conduct the new work in an efficient manner."

Interested in becoming a volunteer?

hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com . By volunteering to take part in one of our studies in a safe, controlled, clinical environment under expertly supervised conditions you are playing your part to further medical research and help increase the understanding of respiratory illnesses.

Individuals interested in taking part in COVID-19 human challenge study research can learn more at www.UKCovidChallenge.com .

For further information please contact:

 Open Orphan plc                                                        +353 (0) 1 644 0007 
 Cathal Friel, Executive Chairman 
 Yamin Khan, Chief Executive Officer 
 Liberum Capital (Nominated Adviser 
  and Joint Broker)                                                    +44 (0) 20 3100 2000 
 Ben Cryer/ Edward Mansfield/ Phil 
  Walker/ Will King 
 finnCap plc (Joint Broker)                                            +44 (0) 20 7220 0500 
 Geoff Nash / James Thompson / Richard 
 Davy (Euronext Growth Adviser and 
  Joint Broker)                                                         +353 (0) 1 679 6363 
 Anthony Farrell 
 Walbrook PR (Financial PR & IR)           +44 (0)20 7933 8780 or openorphan@walbrookpr.com 
  Paul McManus / Sam Allen / Louis                   +44 (0)7980 541 893 / +44 (0) 7502 558 
  Ashe-Jepson                                                                         258 / 
                                                                        +44 (0) 7747 515393 

Notes to Editors

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing contract research company that is a world leader in testing infectious and respiratory disease products using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organisations.

The Company has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing a number of new models, such as malaria and COVID-19, to address the dramatic growth of the global infectious disease market. The Paris and Breda offices have over 25 years of experience providing drug development services such as biometry, data management, statistics CMC, PK and medical writing to third party clients as well as supporting the London-based challenge studies.

Open Orphan runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its newly opened clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. The newly opened facilities have expanded the scope of the business to enable the offering of Phase I and Phase II vaccine field trials, PK studies, bridging studies, and patient trials as part of large international multi-centre studies.

Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company's Disease in Motion(R) platform, this unique dataset includes clinical, immunological, virological, and digital (wearable) biomarkers.

About RSV

RSV is the main cause of childhood lower respiratory infections and is responsible for a significant burden of disease in the elderly and in adults with chronic medical problems, such as COPD. Globally it affects an estimated 50-million people annually, leading to four million hospitalisations and up to 75,000 in-hospital deaths in children under the age of five years. There is a lack of understanding and insight into RSV disease, especially in adult groups, despite its considerable impact on society and its high degree of infectivity.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

May 05, 2022 02:01 ET (06:01 GMT)

Open Orphan (LSE:ORPH)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Open Orphan Charts.
Open Orphan (LSE:ORPH)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Open Orphan Charts.